Overview
Independent life science charity improving patient outcomes.
Founded
1992
Deals · 12mo
3
Stage focus
Geographic focus
Sector focus
Investment portfolio
| NAME | DATE | SIZE | |
|---|---|---|---|
RQ Bio | Jun 2026Participated | $115 MSeries A | |
Cytospire Therapeutics | May 2026Participated | $83 MSeries A | |
Exciva | Jan 2026Participated | $60 MSeries B | |
Tribune Therapeutics | Mar 2025Led | $27 MSeries A | |
Hillstar Bio | Mar 2025Led | $67 MSeries A | |
Maxion Therapeutics | Mar 2025Participated | $78 MSeries A | |
Glox Therapeutics | Jan 2025Led | $0.67 MGrant | |
Fluid Biomed Inc. | Dec 2024Participated | $27 MSeries A | |
Ozlo Sleep | Aug 2023Led | $10 MSeries A | |
Affect Therapeutics | Jul 2023Participated | $16 MSeries A | |
Maxion Therapeutics | Feb 2023Led | $16 MSeries A | |
Surgery Hero | Nov 2022Participated | $2 MSeed | |
RQ Bio | Jun 2026Participated | $115 MSeries A | |
Cytospire Therapeutics | May 2026Participated | $83 MSeries A | |
Exciva | Jan 2026Participated | $60 MSeries B | |
Tribune Therapeutics | Mar 2025Led | $27 MSeries A | |
Hillstar Bio | Mar 2025Led | $67 MSeries A | |
Maxion Therapeutics | Mar 2025Participated | $78 MSeries A | |
Glox Therapeutics | Jan 2025Led | $0.67 MGrant | |
Fluid Biomed Inc. | Dec 2024Participated | $27 MSeries A | |
Ozlo Sleep | Aug 2023Led | $10 MSeries A | |
Affect Therapeutics | Jul 2023Participated | $16 MSeries A | |
Maxion Therapeutics | Feb 2023Led | $16 MSeries A | |
Surgery Hero | Nov 2022Participated | $2 MSeed |
Insights
Time horizon
View by
Deal Distribution
| Round type | Led deals | Participated deals |
|---|---|---|
| Seed | 3 | 2 |
| Series A | 4 | 7 |
| Series B | 0 | 3 |
| Other Equity | 3 | 1 |
| Grant | 1 | 0 |
Monthly Deal Activity
| Month | Deals |
|---|---|
| Sep '17 | 1 |
| Oct '17 | 0 |
| Nov '17 | 0 |
| Dec '17 | 0 |
| Jan '18 | 0 |
| Feb '18 | 0 |
| Mar '18 | 0 |
| Apr '18 | 0 |
| May '18 | 0 |
| Jun '18 | 0 |
| Jul '18 | 0 |
| Aug '18 | 0 |
| Sep '18 | 0 |
| Oct '18 | 0 |
| Nov '18 | 0 |
| Dec '18 | 0 |
| Jan '19 | 0 |
| Feb '19 | 0 |
| Mar '19 | 0 |
| Apr '19 | 1 |
| May '19 | 0 |
| Jun '19 | 2 |
| Jul '19 | 0 |
| Aug '19 | 1 |
| Sep '19 | 0 |
| Oct '19 | 0 |
| Nov '19 | 0 |
| Dec '19 | 0 |
| Jan '20 | 0 |
| Feb '20 | 1 |
| Mar '20 | 1 |
| Apr '20 | 0 |
| May '20 | 0 |
| Jun '20 | 0 |
| Jul '20 | 0 |
| Aug '20 | 0 |
| Sep '20 | 1 |
| Oct '20 | 0 |
| Nov '20 | 0 |
| Dec '20 | 1 |
| Jan '21 | 0 |
| Feb '21 | 0 |
| Mar '21 | 0 |
| Apr '21 | 0 |
| May '21 | 2 |
| Jun '21 | 0 |
| Jul '21 | 0 |
| Aug '21 | 0 |
| Sep '21 | 0 |
| Oct '21 | 0 |
| Nov '21 | 1 |
| Dec '21 | 0 |
| Jan '22 | 0 |
| Feb '22 | 0 |
| Mar '22 | 0 |
| Apr '22 | 0 |
| May '22 | 0 |
| Jun '22 | 0 |
| Jul '22 | 0 |
| Aug '22 | 0 |
| Sep '22 | 0 |
| Oct '22 | 0 |
| Nov '22 | 1 |
| Dec '22 | 0 |
| Jan '23 | 0 |
| Feb '23 | 1 |
| Mar '23 | 0 |
| Apr '23 | 0 |
| May '23 | 0 |
| Jun '23 | 0 |
| Jul '23 | 1 |
| Aug '23 | 1 |
| Sep '23 | 0 |
| Oct '23 | 0 |
| Nov '23 | 0 |
| Dec '23 | 0 |
| Jan '24 | 0 |
| Feb '24 | 0 |
| Mar '24 | 0 |
| Apr '24 | 0 |
| May '24 | 0 |
| Jun '24 | 0 |
| Jul '24 | 0 |
| Aug '24 | 0 |
| Sep '24 | 0 |
| Oct '24 | 0 |
| Nov '24 | 0 |
| Dec '24 | 1 |
| Jan '25 | 1 |
| Feb '25 | 0 |
| Mar '25 | 3 |
| Apr '25 | 0 |
| May '25 | 0 |
| Jun '25 | 0 |
| Jul '25 | 0 |
| Aug '25 | 0 |
| Sep '25 | 0 |
| Oct '25 | 0 |
| Nov '25 | 0 |
| Dec '25 | 0 |
| Jan '26 | 1 |
| Feb '26 | 0 |
| Mar '26 | 0 |
| Apr '26 | 0 |
| May '26 | 1 |
| Jun '26 | 1 |
| Jul '26 | 0 |
| Aug '26 | 0 |
| Sep '26 | 0 |
| Oct '26 | 0 |
Sector Breakdown
A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.
| Sector | Deals |
|---|---|
| Health & Life Sciences | 23 |
| Consumer & Lifestyle | 3 |
| Networks, Cloud & Communication | 1 |
| Hardware & Robotics | 1 |
| Space & Frontier Tech | 1 |
Deal Size Distribution
Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.
| Round size band (USD) | Deals |
|---|---|
| <$5M | 7 |
| $5M-$10M | 2 |
| $10M-$25M | 4 |
| $25M-$50M | 3 |
| $50M-$100M | 5 |
| $100M-$250M | 3 |
| $250M-$500M | 0 |
| $500M-$1B | 0 |
| $1B+ | 0 |
Deals By Geography
Top 3 of 3 regions; European countries are grouped as Europe.
| Region | Deals |
|---|---|
| Europe | 15 |
| United States | 8 |
| Canada | 1 |
Co-Investors
Bubble size = shared deals
Click a bubble to open that fund in a new tab.
Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.
| Co-investor | Shared deals |
|---|---|
| BGF | 3 |
| Monograph Capital | 3 |
| ARTIS Ventures | 2 |
| EQT Life Sciences (LSP) | 2 |
| Frazier Life Sciences | 2 |
| Modi Ventures | 2 |
| Novo Holdings | 2 |
| OrbiMed | 2 |
| Oxford Science Enterprises | 2 |
| Pfizer | 2 |
| 4BIO Capital | 1 |
| Abingworth | 1 |
| Access Biotechnology | 1 |
| Acorn Bioventures | 1 |
| AlleyCorp | 1 |
| Amgen Ventures | 1 |
| Amplitude Ventures | 1 |
| Ananda Impact Ventures | 1 |
| Andera Partners | 1 |
| ArrowMark Partners | 1 |
Investment Strategy
| Category | Deals (count) | Share (%) |
|---|---|---|
| Led | 11 | 46% |
| Participating | 13 | 54% |
| Category | Deals (count) | Share (%) |
|---|---|---|
| Single-lead | 6 | 55% |
| Co-led | 5 | 45% |
Team
Chief Business Officer (CBO)
Non-executive Deputy Chairman, Chair of Audit & Risk Management Committee
Chief Financial Officer